ºÝºÝߣ

oncology cancer targeted therapy personalized healthcare personalized medicine precision medicine big data in oncology ntrk inhibitor ds-6051 dr. martin h. hager venture capital therapy artificial intelligence clinical trial metastasis tumor comprehensive genomic profiling treatment usa innovation prognostic biomarker seed financing globalization department of defense martin h. hager debt financing angiogenesis leadership translocation fund performance ros1 fostering leaders big pharma pharmaceuticals industry mba entrepreneurship daiichi sankyo co. ltd. daiichi-sankyo dr. hager ros1/ntrk inhibitor plexxikon vemurafenib plasticity formin drf3 epithelial mesenchymal transition inhibitor migration emt amoeboid mesenchymal amoeboid transition kinase inhibitor daiichi sankyo ntrk non-small cell lung cancer nsclc arqule peter hirth angel investor digital daiichi-sankyo co. ltd. pharmaceutical ros1 inhibitor taletrectinib astrazeneca pan-tumor tumor-agnostic cancer of unknown primary clinical decision support molecular tumor board cup cupisco clinical study cup-syndrom mtb pathology decision support digital patient monitoring and management diga digitale gesundheitsanwendung tecentriq kaiku health rwd eprom personalised digital health interventions cancer patients capital markets investment economy stock market japan global history of capital markets fundraising germany finance mba practicum phc phc 2.0 foundation medicine flatiron profile sequencing genome oncology pipeline healthcare diagnostics platform diagnostic big data digital strategy digital pathology strategy frankfurter allgemeine zeitung